$0.97
-0.06(-5.61%)
Mkt Cap $11M
$0.81
$2.74
52-Week Range
At a Glance
AI-generatedPersistent operating losses continued amid heavy investment in cell therapy R&D, partially offset by post-IPO cost normalization and strategic asset transactions, as liquidity remains tied to operating and research needs.
6-K
CytoMed Therapeutics reported full-year 2025 financial results with revenue of US$780,857, net loss of US$3.11 million, and cash of US$1.63 million, alongside clinical trial progress and asset acquisitions.$11M
Market Cap
$364.4K
Revenue
-$3M
Net Income
Employees43
Fundamentals
How The Business Makes Money
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Industry Biotechnology
Activity
Company Profile
CIK0001873093
ISINSGXZ17669631
Phone65 6250 7738
Address1 Commonwealth Lane, No. 08-22, Singapore, 149544, SG
SEC EDGAR